Who makes BL1107 High dose?

BL1107 High dose is developed by Bausch & Lomb Incorporated.

What development phase is BL1107 High dose in?

BL1107 High dose is in Phase 2.

What are the side effects of BL1107 High dose?

Common side effects include Corneal edema.

Last reviewed 2026-04-23 · How we verify

BL1107 High dose

Bausch & Lomb Incorporated · Phase 2 active Small molecule

BL1107 High dose is an anti-inflammatory agent.

BL1107 High dose is an anti-inflammatory agent. Used for Treatment of acute postoperative inflammation and pain following cataract surgery.

At a glance

Generic name	BL1107 High dose
Sponsor	Bausch & Lomb Incorporated
Drug class	Anti-inflammatory
Target	COX-2
Modality	Small molecule
Therapeutic area	Ophthalmology
Phase	Phase 2

Mechanism of action

BL1107 High dose works by inhibiting the activity of certain pro-inflammatory enzymes, thereby reducing inflammation and alleviating symptoms associated with various conditions.

Approved indications

Treatment of acute postoperative inflammation and pain following cataract surgery

Common side effects

Corneal edema

Key clinical trials

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results